FleetPulse | $11,000,000 | (May 10, 2024)
ArkeaBio™ | $26,500,000 | (May 10, 2024)
Bluejay Therapeutics | $182,000,000 | (May 10, 2024)
BenchSci
Canada
- Toronto, Ontario
- 24/01/2022
- Series C
- $63,000,000
BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. To achieve this, we're exponentially increasing the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence.
Backed by F-Prime, Gradient Ventures (Google’s AI fund), Inovia Capital, and TCV, our platform accelerates science at 16 of the top-20 pharmaceutical companies, and over 4,300 leading research centers worldwide.
We’re a remote-first company recognized for our impact and culture as a Deloitte Tech Fast 50TM, CIX Top 10 Growth, Great Place to Work®, and top-ranked organization on Glassdoor.
- Industry Software Development
- Website https://www.benchsci.com/
- LinkedIn https://www.linkedin.com/company/benchsci/about/
Related People
Tom Leung, MSc PhDFounder
Canada -
Toronto, Ontario
--BenchSci: Search By Evidence--
Researchers often look for evidence-of-use in literature before buying a new antibody or reagent. BenchSci aim to provide value for scientists, providing quick and easy access to evidence-of-use for different antibodies and reagents in peer-reviewed literature. Through BenchSci, scientists will be able to search antibodies or reagents by evidence and validations.
CoverTree | $13,000,000 | (May 10, 2024)
Li Industries | $36,000,000 | (May 10, 2024)
Archive Intel | $1,000,000 | (May 10, 2024)
Little Sparrows Technologies | $3,000,000 | (May 10, 2024)
Triomics | $15,000,000 | (May 10, 2024)
Altera | $9,000,000 | (May 10, 2024)
Electricity Maps | $5,390,775 | (May 10, 2024)
Sift Healthcare | $20,000,000 | (May 10, 2024)
Aardvark Therapeutics | $85,000,000 | (May 10, 2024)
Chip City | $7,500,000 | (May 10, 2024)